for the measurement of unconjugated 17j#-estradiol in as little as 0.01 ml of pregnancy plasma employing rabbit uterine cytosol as specific binder and activated charcoal as nonspecific adsorbant. Large numbers of samples could be processed simultaneously at relatively little expense and results were obtainable within 3 hr. The procedure was sensitive to 1 ng/ml. No diurnal or positional variations were found. Values from 250 unselected normal patients showed a constantly rising mean plasma E2 from 18 to 35 wk gestation from 4.5 to 14 ng/ml. From 35 to 40 wk, mean E2 rose only to 15 ng/ml and the range of values increased substantially. When 22 normal pregnant subjects were followed serially, rising levels of plasma E2 were found with no significant fall ever seen. By contrast, patients exhibiting fetal distress generally had falling or reduced E2 levels. However, 3 cases of Rh isoimmunization had elevated or normal E2 concentrations even after clearcut evidence of fetal demise. A decrease of 45% in E2 concentration was associated with intraamniotic instillation of hypertonic saline prior to delivery supporting the view that placental conversion of maternal adrenal precursors is responsible for about half of the Ea production in pregnancy. The postpartum clearance of endogenous E2 was measured and found to fit a two compartment model with mean half-time of 22 min and 7 hr. Follicular phase levels of E2 were attained by 35 hr postpartum. The concentration of unconjugated E2 in pregnancy plasma correlated as well with the state of the placenta as other placental hormone measurements and holds promise of being a rapid, inexpensive, and reliable method of following patients with high-risk pregnancies in a variety of clinical settings.
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INTRODUCTION
Since the discovery of Spielman, Goldberger, and Frank in 1933 (1) that, upon the death of the fetus, urinary bioassayable estrogens decrease markedly, it has been clear that this phenomenon might have clinical applications in assessing fetoplacental function.
Subsequently, with the development of steroid measurement methods, estimation of the urinary estriol (E3)' has been used extensively for assisting the obstetrician in the diagnosis of fetal distress. Aside from technological problems which have been gradually overcome, urinary E3 assay has intrinsic disadvantages.
The need to collect urine results in errors if there are incomplete 24 hr collections. Because of dependance on hepatic conjugation and renal clearance wide daily variations in urinary E& excretion have been described (2) (3) (4) (5) (6) , increasing the complexity of clinical interpretation.
Measurement of the plasma E3 (6, 7) has not attained widespread acceptance, perhaps because of technical difficulties, but results may be obtained within a single day. A search for other means of evaluating placental function has been carried out recently. Plasma levels of various hormones (8, 9), blood components (10) , and enzymes (11, 12) have been suggested as criteria of assessing placental function and some of these techniques such as blood human chorionic somatomammotropin (placental lactogen) termed (HCS) (9) are promising.
Development in our laboratories of a radioligand assay method for the measurement of unconjugated 17p-estradiol (E2) (13) (14) (15) and estrone (E1) (16) pregnant individuals led us to explore the possibility of measuring E2 in pregnancy plasma and testing its effectiveness as a predictor of fetal distress.
We now report an extremely simple, inexpensive, and rapid technique for the radioligand assay of unconjugated plasma E2 in pregnancy. A single individual can reliably measure the concentration of E2 in large numbers of plasmas in 3 hr using minute amounts of blood.
Over 250 sequential and individual estrogen determinations have revealed the pattern of change during normal pregnancy and have demonstrated the alterations in 16 cases of fetal distress. Changes in the plasma E2 resulting from induction of abortion using hypertonic saline infusion have been characterized. The pattern of decline of endogenous E2 from the time of parturition has been shown.
On the basis of these data it is suggested that measurement of E2 during pregnancy by the radioligand assay procedure may provide considerable physiological information and may be of significant clinical applicability, particularly in the early diagnosis of placental insufficiency. The subj ects were all volunteers who gave informed written consent. For the postpartum studies, the subj ects were housed in the Harbor General Hospital Clinical Research Center.
METHODS
Assay Procedure. The specific estrogen binder was prepared from immature rabbit uteri as previously described (13) (14) (15) . Fresh or freshly frozen uteri from immature rabbits were obtained from a commercial slaughterhouse. Uterine estrogen binder has been prepared successfully from rat, calf, horse, and human uterus (15) as well as rabbit. Uteri were homogenized in 3 volumes of a buffer consisting of 0.01 M Tris-HCl pH 8.0, 0.001 M EDTA, 0.25 M sucrose, at 4°C in the Waring Blendor using four 30-sec pulses and cooling intervals of 2 min. The homogenate was centrifuged at 1000 g for 15 min and the supernatant centrifuged at 105,000 g for 90 min at 4°C. This supernatant (cytosol), stored in liquid N2 in small portions, was stable as a potent estrogen binder for months.
The E2 assay was carried out in 10 X 75 mm disposable glass centrifuge tubes. Radioactive E2 and standard E2 solutions, were made up in assay buffer consisting of 8 volumes 0.01 M Tris-HCl pH 8.0, 0.001 M EDTA, and 2 volumes of ethylene glycol. To a final vol of 0.5 ml were added either was attained. Furthermore, dried ether extracts of 0.2 ml of 0.02 ml of plasma and 10,000 cpm of 'H-labeled E2. The final addition was 0.02 ml of uterine cytosol. Each assay consisted of a standard curve in triplicate and unknowns in (14) . For unknowns run at 0.01 ml, then, the sensitivity of the assay was 2 ng/ml. We found that the use of 0.020 ml of plasma did in no way alter the assay so that under those circumstances a sensitivity of 1 ng/ml was attained. Furthermore, dried ether extracts of 0.2 ml of plasma or less also gave identical plasma concentration values at a sensitivity of 0.1 ng/ml. Blanks using nonpregnancy plasma gave values indistinguishable from 0. The precision of the assay system has been previously evaluated (14) with an index of precision X of the standard curve of 0.06. A number of studies have been carried out to validate the specificity of the estrogen assay system. Specificity of the uterine receptor for estrogens has been demonstrated (13, 17) . Comparability of estrogen measurements with those of Baird and Guevara, using a double isotope derivative procedure (18) , has supported the validity of radioligand assay.
In the case of pregnancy plasma, conditions were required which could minimize the contribution of the E1, E3, and estrogen conjugates present. Accordingly, conditions were employed in which the ratio of association constants (19) of E1 and estriol relative to E2 were low (Table I) . In contrast to overnight incubation at 0°C, after incubation at 230C for 2 hr, E1 and E3 had affinities only 8 and 5% that of E2 for the uterine receptor. It has been our experience that estrogen conjugates do not bind to the uterine cytosol. receptor. However, to demonstrate the lack of influence of any component of pregnancy plasma on the plasma E2 determination, we have carried out a comparison of the above procedure with replicates assayed as previously described (13) (14) (15) . Other estrogens and estrogen conjugates were separated from the E2 fraction by ether extraction and
The Plasma Estradiol as an Index of Fetoplacental Function Samples of pregnancy plasma were assayed by the simple and themore complex radioligand assay procedures described in the text and the values obtained compared. The mean E2 was 9.45 ng/ml on direct assay and 9.65 ng/ml for extracted and chromatographed plasma.
column chromatography, and recovery was estimated by an internal standard. As shown in Table II , the mean E2 was 9.45 ng/ml on direct and 9.65 ng/ml on processed plasma, an insignificant difference. The mean SD of duplicates run by the different methods was 0.8 ng/ml. Duplicate plasmas run by the "direct" method only, on different days, also gave a constant SD of 0.8 ng/ml. The probability was, therefore, less than 5% that another portion assayed by the same method would vary by more than 1.6 ng/ml. Further evidence for the validity of the method has been obtained by comparison with values obtained by others during gestation. Very good agreement with the data of Svendsen and Sorensen (20) , Smith (21) , and Munson, Mueller, and Yannone (22) , all of whom used quite different techniques, has been obtained. Table III , no significant fluctuations in Es levels were found.
The effect of short-term postural changes on blood E2 were checked in patients from whom blood was drawn after 30 min of stabilization in each given position. There was no difference from one position to another.
Blood was drawn from 250 unselected patients visiting the prenatal clinic. Their plasma E2 values are shown in Fig. 1 retardation. She had 3+ proteinuria and a blood pressure of 160/100. The uterus was the size of a 22-wk gestation and fetal heart tones were present. Her blood pressure was controlled with hydralazine over the next 4 wk but no increase in uterine size was noted. Fetal movements and then fetal heart tones ceased and the patient was delivered of an 1100 g macerated fetus by the instillation of hypertonic glucose intraamniotically. The placenta weighed 250 g and had multiple infarcts.
The plasma E2 hovered at the lower limit of normal for a 26 wk gestation and fell before fetal demise.
Patients with Rh isoimmunization disease
Patient Rhl was a 26 yr old, gravida 3, para 2. Her plasma E2 was abnormally high for her stage of gestation and continued to be elevated after fetal death.
Patient Rh2 was a 23 yr old, gravida 3, para 2, whose severe Rh isoimmunization disease necessitated intrauterine fetal transfusion. Fetal death ensued and she went into spontaneous labor 1 day later. Her E2 levels, initially elevated, fell only to the normal range after fetal demise.
Patient Rh3 was a 22 yr old, gravida 3, para 2, who presented at 30 wk of gestation with evidence of intrauterine fetal demise. Her initial E2 was in the normal range and although it fell significantly 1 wk later it remained in the normal range despite unequivocal evidence for fetal demise.
Measurement of the plasma E2 would have been of assistance in predicting imminent fetal demise in cases 1, 2, 11, 12, 13, and 14. In patients 4, 5, and 6, the clinical presentation was too late for fetal salvage. The value in patient 7, was clearly misleading and in 9, a normal plasma E2 concentration failed to reveal imminent fetal demise or placental infarction. In the three cases of Rh isoimmunization disease, E2 levels were elevated or normal even in the face of fetal demise.
Induced abortions
The disappearance rate of E2 was determined in nine patients at from 14 to 20 wk gestation who underwent therapeutic abortion by the infusion of hypertonic saline intraamniotically for 10 min. Blood was obtained before the procedure. and at the times indicated in Fig. 4 . The mean initial plasma E2 was 4.0 ng/ml. By 6 hr, 6 of the patients had attained their maximum fall. At 20 hr, before delivery, the mean value had fallen only to 2. MINUTES POST PARTUM FIGuRE 5 Plasma levels of E2 during the 1st hr postpartum period. Per cent refers to the prepartum concentration of E2. Delivery was accomplished in each of these patients in less than 10 min. pregnancy. Her initial value of 800 pg/ml fell to 200 pg/ml, a value in the nonpregnant range.
Postpartum E2 clearance
In order to study the disappearance rate of E2 from the blood, we selected four volunteers who had had an uneventful labor and delivery, and who had not received lactation suppressants. The initial blood sample was drawn upon delivery of the baby's head and subsequently in frequency ranging from 10 min in the first postpartum hr to 6 hr on the 3rd postpartum day. During the first 24 hr, blood was drawn through a heparinized catheter which was removed thereafter and the total amount of blood obtained from each patient did not exceed 75 ml. From three other patients, blood samples were drawn in the 1st postpartum hr only. Sensitivity of the assay system was adapted to the anticipated concentration of E2. After 3 hr each sample was analyzed by the method for nonpregnant individuals previously described.
The results for the 1st hr are depicted in Fig. 5 . The data are presented as per cent of the initial concentration. The mean initial half-life of the hormone was 22 min. Four of the seven had initial E2 half-lives of 13 min and the other three 27, 30, and 45 min respectively. Subsequent determinations are presented in Fig. 6 . A second exponential decay with half-lives of 6, 6, 6, and 8 hr was apparent. Normal early follicular phase values for E2 of under 100 pg/ml were reached in each case by 35 hr postpartum. 
DISCUSSION
We have exploited the intracellular estrogen receptor characteristic of target tissues for steroid hormones as specific binding reagent for unconjugated estrogen assay in male and female blood plasma (13) (14) (15) (16) . During human pregnancy, there are markedly elevated concentrations of unconjugated estrogens present which made it possible for us to simplify the assay procedure by elimination of the extraction and chromatographic steps. This reduced the time required for the assay to 3 hr and increased the number of samples, which could be processed enormously, while reducing costs substantially.
We were able to show that neither the numerical value nor the precision of the assay was affected by the simplification, also ensuring that we were not measuring estrogen conjugates. Since we could use up to 0.02 ml of plasma, the lower limit of sensitivity of the assay was 1 ng/ml. In the last trimester of pregnancy the vast bulk of determinations were over 8 ng/ml ( Fig. 1 ) and the coefficient of variation of replicates was < 10% at this concentration or above.
We found that the mean plasma E2 concentration rose at a fairly constant rate during pregnancy until the 35th wk when the rate of increment decreased. Values at term tended to become more variable ranging from 5.5 to 50 ng/ml (in one instance). These results confirmed previous reports (20) (21) (22) using entirely different assay methods; the validity of our procedure was hence indirectly supported. A declining rate of increase in late pregnancy has been shown to be characteristic of the other principal placental hormones progesterone (23, 24) and chorionic somatomammatropin (8, 25) .
Of note is the fact that in studies of normal pregnancy, from the 32nd wk no E2 level below 5.5 ng/ml was found (Fig. 1 ) and no significant decline occurred during the course of gestation (Fig. 2) . By contrast, in each abnormal pregnancy followed serially (Fig. 3) , except in Rh isoimmunization disease, falling E2 levels and abnormally low concentrations were found, suggesting that particularly in cases of placental insufficiency, following the plasma E2 may be of clinical assistance. Unfortunately we had no diabetic pregnancies.
The high E2 concentrations persisting after evidence of fetal demise in Rh isoimmunization disease (Fig. 3) are consistent with values obtained for plasma (7) , and urinary estriol (25) (26) (27) (28) , as well as chorionic somatomammatropin (25) , when these assays were used to evaluate fetal well being. It is generally accepted that the placenta is hypertrophied in both Rh isoimmunization disease and many diabetic pregnancies, resulting in persistence of normal hormone values despite clear evidence of prior fetal demise. In cases of placental insufficiency however, the plasma E2 assay provides as good evidence of the clinical state as any other hormone measurement.
Estimation of the clinical usefulness of any of the hormonal parameters of fetoplacental well being is difficult because the clinical setting in which the assays are performed is of importance. Under conditions of nearly continuous fetal monitoring, clinical evaluation may be more satisfactory than any test with a time delay. However, as previously emphasized (7, (27) (28) (29) a fall of serially obtained urinary or plasma E2 concentrations strongly suggested imminent fetal distress so that significant fetal salvage might be anticipated by appropriate follow-up procedures in general prenatalcare clinics or particularly in high-risk clinics. Our data indicate that measurement of the plasma E2 can give similar if not superior information. Therefore it is suggested that this rapid, simple, and inexpensive assay may be of considerable help in identifying and following patients suspected of placental insufficiency.
In study of induced abortion at 14-20 wk gestation, the fall in E2 concentration after fetal death, which presumably represents the fetal contribution, averaged only 40% (Fig. 4) . The persistently high plasma concentrations at 20 hr were probably due to a continued supply of 'precursors by maternal adrenals and the presence of an intact placenta. Persistence of the plasma progesterone (30) and human chorionic gonadotropin (HCG) (8) under similar conditions attests to the viability of the placenta and supports the quantitative contribution of adrenal sources to E2 secretion at this time of pregnancy. The patient with suppressed adrenals had a fall of E2 to 200 pg/ml. The source of this concentration of E2, a normal luteal phase level, was not clear but presumably ovarian and fetal adrenal sources may contribute.
The half-life of unconjugated E2 has been reported to be about 20 min based on studies measuring the disappearance rate of intravenous tracers in nonpregnant women (31) . We have taken a different approach and measured the disappearance of endogenous hormone from the blood postpartum. Assuming a linear initial disappearance, the mean first half-times of the hormone was found to be 22 min with a range of from 13 to 45 min (Fig. 5) . In the four cases, followed for more than 1 hr (Fig. 6) , a two compartment model can be shown to characterize the vast bulk of E2 clearance, with a mean second ti of 6-7 hr and a range of from 6 to 8 hr. The E2 concentration reached follicular phase levels by 14-35 hr, similar to the fall of progesterone (23, 24) at a time when plasma HCG levels remained quite high (32, 33) . These data directly support the view that HCG does not stimulate estrogen secretion by the ovary of pregnancy. Previous studies (22) , though confirmatory, were not sensitive enough to delineate the lower portion of the curve. The physiological significance of these two compartments is not known.
